---
search:
  boost: 3
---

# Colony Stimulating Factors

This is a subcategory of Blood Formation, Coagulation, and Thrombosis Agents.

## Decision Trees

- [Blood Products - Colony Stimulating Factors- Non-Preferred - Savaysa, Xarelto Suspension, Dabigatran(Pradaxa P, BvG)](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURVNBTjhJQlpPMlE5RFNWV1BSMVFJRDVORCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Blood Products - Colony Stimulating Factors - Non-Preferred - Fulphila, Fylnetra, Granix, Leukine, Neulasta, Releuko, Udenyca, Zarxio](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMjlISUY2UjhXUlVDUjJNTExLSVhSOTRHVyQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Blood Products - Colony Stimulating Factors - Preferred Agents - Neupogen, Nivestym, Nyvepria, Ziextenzo](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURTQ5OFJRTlJWTDFDQVpYQUpYNjUyOTlHRiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred               | Generic Name | Quantity | Time (Days) |
|:------------------------|:-------------|:--------:|:-----------:|
| Neupogen <sup>PA</sup>  |              |          |             |
| Nivestym <sup>PA</sup>  |              |          |             |
| Nyvepria <sup>PA</sup>  |              |          |             |
| Ziextenzo <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
|:--------------|:-------------|:--------:|:-----------:|
| Fulphila      |              |          |             |
| Fylnetra      |              |          |             |
| Granix        |              |          |             |
| Leukine       |              |          |             |
| Neulasta      |              |          |             |
| Releuko       |              |          |             |
| Udenyca       |              |          |             |
| Zarxio        |              |          |             |

## Authorizations

**Length of Authorizations**: Dependent upon diagnosis below

| Diagnosis                                                                                                                                                                           | Approval Length                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Acute Myeloid Leukemia (AML)                                                                                                                                                        | 14 days or duration of chemotherapy regimen |
| Malignancy at risk for febrile neutropenia or undergoing myeloablative chemotherapy prior to allogeneic or autologous bone marrow transplantation                                   | 14 days or duration of chemotherapy regimen |
| Myeloid Engraftment for bone marrow transplant (BMT)                                                                                                                                | 30 days                                     |
| Severe, chronic neutropenia with absolute neutrophil count (ANC) of less than 500/mm3 and have symptoms associated with neutropenia (e.g. fever, infections, oropharyngeal ulcers). | 30 days                                     |
| Hematopoietic radiation injury syndrome                                                                                                                                             | 30 days                                     |

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Must provide documentation of diagnosis, patient's weight, and duration of treatment

### Non-Preferred

Non-Preferred Criteria

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

-   Must provide documentation of patientâ€™s clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=13){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=9){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
